Slingshot members are tracking this event:

Exelixis and Its Partner Ipsen Announce Phase 3 Trial Results of CABOMETYX (Cabozantinib) Tablets Demonstrating Significant Overall Survival Benefit for Previously Treated Patients with Advanced Renal Cell Carcinoma Presented at ASCO

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
EXEL Community voting in process
I7G.F Community voting in process

Additional Information

Clinical Data At the time of the analysis, the median duration of treatment in the trial was 8.3 months with CABOMETYX versus 4.4 months with everolimus. Dose reductions occurred for 62 percent and 25 percent of patients, respectively. Discontinuation rate due to an adverse event not related to disease progression was 12 percent with CABOMETYX and 11 percent with everolimus.
The most common grade 3 or 4 adverse events were hypertension (15 percent), diarrhea (13 percent) and fatigue (11 percent) in the CABOMETYX arm and anemia (17 percent), fatigue (7 percent) and hyperglycemia (5 percent) in the everolimus arm. Serious adverse events ≥ grade 3 occurred in 130 (39 percent) of cabozantinib-treated patients and in 129 (40 percent) of everolimus-treated patients.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 05, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cabometyx, Cabozantinib, Advanced Renal Cell Carcinoma, Everolimus